Multiparametric MRI of the Prostate: Beyond Cancer Detection and Staging
Menée à partir de données portant sur 79 patients atteints d'un cancer de la prostate traité par prostatectomie radicale entre 2008 et 2016, cette étude identifie les résultats ou paramètres, issus d'une IRM multiparamétrique pré-opératoire ou d'une analyse immunohistochimique d'échantillons biopsiques obtenus à l'aide d'un guidage par IRM, permettant de prédire le risque de récidive biochimique post-opératoire
Prostate cancer is a common and heterogeneous condition. It ranges from indolent low-grade disease—which many experts argue would be better left undetected—to lethal forms warranting early detection and prompt treatment. Despite a 5-year survival rate of 98%, it represents the second most common cause of cancer-specific death in men (1). More men with low-risk disease are adopting active surveillance, which is encouraging (2). However, up to 50% of men with indolent forms of the disease undergo radical prostatectomy or radiation therapy (3). The uncertainty of active surveillance and the legal, cultural, and financial forces partly explain this bias toward treatment (4). Many men with presumed localized prostate cancer who undergo surgery experience biochemical recurrence. This indicates that local surgical treatment alone may not provide adequate disease control.
Radiology , éditorial, 2020